Analytical Data
-
基因名
TM4SF1 Protein-VLP
- Application
-
别名
Membrane component chromosome 3 surface marker 1 Tumor-associated antigen L6
-
种属
Human
-
表达系统
Yeast
-
标签
N- His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P30408
-
表达区间
115-161aa
-
分子量
7.3 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TM4SF1, a member of the tetraspanin family, is known to play a crucial role in various cellular processes, including cell proliferation, differentiation, and migration. Recent studies have highlighted its potential involvement in cancer progression and immune modulation, making it an attractive target for therapeutic strategies. The use of virus-like particles (VLPs) as a platform for vaccine development and protein delivery has gained significant attention due to their natural ability to elicit robust immune responses. The recombinant expression of TM4SF1 in VLPs presents an innovative approach to harnessing its biological functions while enhancing the immunogenicity of the protein. This strategy not only facilitates the investigation of TM4SF1's role in pathophysiology but also offers a promising avenue for vaccine design against tumors or infectious diseases. By presenting TM4SF1 in a VLP format, researchers aim to improve its stability, facilitate targeted delivery, and evoke a stronger immune response, thereby advancing therapeutic options. Continued research in this domain could pave the way for novel treatments that exploit the unique properties of TM4SF1 and VLPs.
